Fundraising FoxAndera Partners — 2018 Investments
7 investments dated 2018 · listed companies and verified rows first · show all
Enyo Pharma is a biotechnology company focused on drug development in the life sciences and therapeutics field.
BiotechHealthtechMedical DevicesLyon, FR
Jacky Vonderscher(Co-founder & CEO)inLaurène Meyniel-Schicklin(Founder, Head of Bioinformatics)inBenoît de Chassey(Founder, Head of Drug Discovery Platform)inPatrice André(Founder, Medical Advisor)inVincent Lotteau(Founder, Advisor)Jean-Jacques Garaud(Co-founder)in
Co-investorsOrbiMedSofinnova PartnersBpifrance
Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.
BiotechHealthtechMedical Devices
Co-investorsDementia Discovery FundM VenturesNovartis Venture FundPfizer Venture InvestmentsRA CapitalSofinnova Partners+6 more
Loyalty Company is a consulting group focused on data marketing and communication, combining strategic consulting, technology solutions, and operational services to help companies manage the customer value chain.
AdTechData & InfrastructureMarketing TechVirginia Beach, US
John T. Hewitt(Executive Officer, Director)in
Reviral operates an affiliate review site that ranks and reviews online casinos not registered with the UK's GamStop self-exclusion scheme, comparing licences, bonuses, wagering terms, payout speeds, and payment methods.
ConsumerMedia & Entertainment
Co-investorsBrace PharmaNew Leaf Venture PartnersOrbiMedWellcome Trust
TRiCares develops the Topaz Transfemoral Tricuspid Heart Valve Replacement (TTVR) System, a minimally invasive device for treating tricuspid regurgitation.
BiotechHardwareHealthtechMedical DevicesFrance, FR
Ahmed Elmouelhi(President & CEO)inEsther Gerteis(Senior VP Medical & Regulatory Affairs)inMichael Litzenburger(VP R&D)in
Co-investorsEuropean Investment Bank415 CapitalBayern KapitalBioMedPartnersKarista
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.